Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Glenn Van Hulst

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
International Journal of Molecular Sciences|September 28, 2021
Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity?Glenn Van Hulst, Fabrice Bureau, Christophe J Desmet
Biochemical Pharmacology|April 12, 2020
Eosinophil diversity in asthmaGlenn Van Hulst, Hashini M Batugedara, Joseph Jorssen, et al.
The European Respiratory Journal|September 3, 2021
Anti-IL5 mepolizumab minimally influences residual blood eosinophils in severe asthmaGlenn Van Hulst, Joseph Jorssen, Nathalie Jacobs, et al.
The European Respiratory Journal|July 1, 2022
Reply: <i>Ex vivo</i> SOCS3 gene responsiveness to alarmins in eosinophils of mepolizumab-treated patients is as yet of unknown biological significanceGlenn Van Hulst, Joseph Jorssen, Nathalie Jacobs, et al.
Immunity|May 22, 2024
Single-cell proteomics and transcriptomics capture eosinophil development and identify the role of IL-5 in their lineage transit amplificationJoseph Jorssen, Glenn Van Hulst, Kiréna Mollers, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
International Journal of Molecular Sciences|September 28, 2021
Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity?Glenn Van Hulst, Fabrice Bureau, Christophe J Desmet
Biochemical Pharmacology|April 12, 2020
Eosinophil diversity in asthmaGlenn Van Hulst, Hashini M Batugedara, Joseph Jorssen, et al.
The European Respiratory Journal|September 3, 2021
Anti-IL5 mepolizumab minimally influences residual blood eosinophils in severe asthmaGlenn Van Hulst, Joseph Jorssen, Nathalie Jacobs, et al.
The European Respiratory Journal|July 1, 2022
Reply: <i>Ex vivo</i> SOCS3 gene responsiveness to alarmins in eosinophils of mepolizumab-treated patients is as yet of unknown biological significanceGlenn Van Hulst, Joseph Jorssen, Nathalie Jacobs, et al.
Immunity|May 22, 2024
Single-cell proteomics and transcriptomics capture eosinophil development and identify the role of IL-5 in their lineage transit amplificationJoseph Jorssen, Glenn Van Hulst, Kiréna Mollers, et al.
Pageof 1